Dr Melissa Hudson comments on the study findings study findings, where a team found two targeted therapies, dabrafenib (taflinar) plus trametinib (mekinst), significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in paediatric patients with BRAF V600 mutation-positive low-grade gliomas.
Dr Hudson discusses the significance of the findings, which will reduce the long term impact of adverse outcomes for paediatric patients.
Read the news story here
Watch Dr Bouffet's press conference video here
Watch Dr Bouffet's interview on the study here